Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
FT500
FATE THERAPEUTICS INC
Advanced Solid Tumors
1 trial -
FT516
FATE THERAPEUTICS INC
Acute Myelogenous Leukemia
1 trial -
FT516
FATE THERAPEUTICS INC
Solid Tumor, Adult
1 trial -
FT522
FATE THERAPEUTICS INC
Relapsed/Refractory B-Cell Lymphoma
1 trial -
FT536
FATE THERAPEUTICS INC
Non Small Cell Lung Cancer
1 trial -
FT536
FATE THERAPEUTICS INC
Astrocytoma
1 trial -
FT538
FATE THERAPEUTICS INC
Solid Tumor, Adult
1 trial -
FT538
FATE THERAPEUTICS INC
Acute Myeloid Leukemia
1 trial -
FT576 (Allogenic CAR NK cells with BCMA expression)
FATE THERAPEUTICS INC
Multiple Myeloma
1 trial -
FT596
FATE THERAPEUTICS INC
Diffuse Large B Cell Lymphoma
1 trial -
FT596
FATE THERAPEUTICS INC
Lymphoma, B-Cell
1 trial -
FT819
FATE THERAPEUTICS INC
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)
1 trial -
FT819
FATE THERAPEUTICS INC
Lymphoma, B-Cell
1 trial -
FT819 in B-cell Mediated Autoimmune Diseases
FATE THERAPEUTICS INC
B-cell Mediated Autoimmune Diseases
1 trial -
FT825
FATE THERAPEUTICS INC
Advanced Solid Tumor
1 trial -
FT836
FATE THERAPEUTICS INC
Non-Small Cell Lung Cancer
1 trial -
Fexofenadine Hydrochloride without sodium lauryl sulfate
BRIGHT MINDS BIOSCIENCES INC.
The Impact of Excipients on Drug Absorption
1 trial -
Fludarabine
FATE THERAPEUTICS INC
Hematologic Malignancies
1 trial -
Morphine Sulfate
BRIGHT MINDS BIOSCIENCES INC.
Opioid Use Disorder
1 trial -
ProHema-CB Transplant
FATE THERAPEUTICS INC
Metabolic Disorders
1 trial -
Single FT1050 treated UCB unit
FATE THERAPEUTICS INC
Non-Hodgkin's Lymphoma (NHL)
1 trial -
ESTECLIN 300 MG CAPSULE RIGIDE
FATE THERAPEUTICS INC
COPD
1 trial -
Hydroxychloroquine Sulfate
First Tracks Biotherapeutics
Primary IgA Nephropathy
1 trial -
Hydroxychloroquine Sulfate 200 Mg Tablet
First Tracks Biotherapeutics
Atrial Fibrillation
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources